IASLC 2020 World Conference on Lung Cancer: Singapore Highlights
In this recorded webinar, Dr. Yi-long Wu, Dr. Daniel Tan and Dr. Ross Soo discuss key abstracts, presentations, and developments reported during the IASLC 2020 World Conference on Lung Cancer: Singapore.
This webinar is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants.
At the conclusion of this activity, participants will be able to:
- Describe scientific progress in the prevention, early detection, diagnosis, and treatment of thoracic malignancies.
- Explain advances in the multidisciplinary management of patients in relation to current standards of care.
- Identify the most relevant clinical research results and ongoing trials likely to impact patient care in the near future.
Advisory Board: Novartis, Bayer, Boehringer Ingelheim, Astra Zeneca, Eli-lily, Loxo, Pfizer, MSD. Contracted/Support research grant: Novartis, Astra Zeneca, GlaxoSmithKline, Bayer, Pfizer.
Advisory Board: AstraZeneca, Boehringer Ingelheim. Honorarium received from promotional activities: AstraZeneca, Roche, Boehringer Ingelheim, Pfizer, BMS, MSD, Eli Lilly (all not promotional activities). Contracted/Support Research Grant: AstraZeneca, Roche, Boehringer Ingelheim.
Contracted/Support research grant: AstraZeneca, and Boehringer Ingelheim. Personal fees: Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer,Roche, Taiho, Takeda, Yuhan, Amgen.
None of the other individuals involved in the planning or review of the activity have disclosed any relevant financial relationships.
Yi-long Wu, MD
Head of Department
Guangdong Lung Cancer Institute
Guangdong General Hospital and Guangdong Academy of Medical Sciences
Daniel SW Tan, MD
Division of Medical Oncology
National Cancer Centre Singapore
Ross Soo, MBBS, RACP
Senior Consultant at the Department of Haematology-Oncology, NCIS
Adjunct Principal Investigator, Cancer Science Institute of Singapore, NUS
AMA PRA Category 1 Credit™ is no longer available for this activity.
- 1.00 Attendance